Real‐world expectation in Helicobacter pylori eradication of patients in Taiwan—A pilot shared decision‐making survey
Advances in Digestive Medicine · 2026-09 · 13 (3)
DOI: 10.1002/aid2.70040 ↗Abstract
Abstract Helicobacter pylori infection remains a major cause of peptic ulcer disease and gastric malignancy. Increasing antibiotic resistance has reduced the efficacy of conventional triple therapy, prompting the introduction of alternative regimens. Shared decision‐making (SDM) can improve patient satisfaction and adherence, yet patient expectations in Taiwan remain under‐explored. A cross‐sectional, questionnaire‐based survey was conducted at three hospitals in southern Taiwan (Kaohsiung Medical University Hospital, An‐Nan Hospital, and Pingtung Christian Hospital) to assess patients' preferences and expectations for H. pylori eradication therapy. Eligible participants were adults who had received or were receiving eradication treatment. The questionnaire included items on demographics, preferred regimens, most‐concerned factors, and minimal acceptable eradication rates. Among 503 valid responses, most patients (80.3%) regarded eradication rate as the most important factor, followed by side effects (17.1%) and cost (2.6%). The mean minimal acceptable eradication rate was 90.2% (95% CI: 85.2–90.8). The 14‐day hybrid/reverse‐hybrid therapy was the most preferred regimen (72.6%), followed by 7‐day standard triple therapy (17.1%) and 14‐day bismuth quadruple therapy (4.6%). This first patient‐focused, multi‐center SDM survey in Taiwan revealed that most patients prioritize high eradication efficacy and favor the 14‐day hybrid/reverse‐hybrid regimen. These findings highlight a gap between patient and physician preferences and underscore the need to incorporate patient perspectives into routine clinical decision‐making and future guideline updates.
EUVIMED